FAS and steatosis: The FAS inhibitor (FT-4101) safely reduced hepatic DNL and steatosis of patients with NASH in a phase 1/2 clinical trial (NCT04004325).92 Another FAS inhibitor Orlistat, however, did not enhance weight loss or improve liver enzymes, measures of IR, and histopathology (NCT00160407).93